Delve Bio's Metagenomic Sequencing Test Shows Promise for Faster Meningitis/Encephalitis Diagnosis
Key Insights
A study published in Open Forum Infectious Diseases demonstrates that earlier use of Delve Bio (search)'s metagenomic next-generation sequencing (mNGS) test could reduce diagnostic testing by up to 92% and shorten time to diagnosis by over 10 days for certain patient populations.
The comprehensive mNGS testing technology, available through Delve Detect (search), can identify RNA and DNA pathogens within 48 hours and provides 22% greater diagnostic yield compared to traditional methods.
Real-world data shows the test could eliminate hundreds of unnecessary tests and reduce hospital stays for patients with meningitis (search)/encephalitis (search), offering significant cost savings at both patient and institutional levels.
A new study suggests that earlier implementation of comprehensive metagenomic next-generation sequencing (mNGS) could dramatically reduce the diagnostic burden for patients with meningitis (search) and encephalitis (search) while accelerating time to treatment. The research, published in Open Forum Infectious Diseases, examined the potential clinical impact of Delve Bio (search)'s Delve Detect (search) test, which can identify both RNA and DNA pathogens within 48 hours.
Significant Reduction in Diagnostic Testing
The study modeled outcomes for two distinct patient cohorts: those with infectious meningitis (search)/encephalitis (search) and those with autoimmune encephalitis (search). Researchers analyzed what would have occurred if mNGS testing had been implemented early in the diagnostic workup, specifically after the first lumbar puncture.
The results revealed substantial potential improvements in diagnostic efficiency. For patients with infectious meningitis (search)/encephalitis (search), nearly 64% of microbiological tests could have been avoided, shortening time to diagnosis by nearly seven days per patient. The impact was even more pronounced in the autoimmune encephalitis (search) cohort, where 92% of tests could have been eliminated, saving over 10 days to diagnosis per patient.
"The cause of as many as half of all cases of meningitis (search)/encephalitis (search) is never identified, and mNGS has emerged as an important tool in the clinical workup of these infections," said Kiran Thakur, Herbert Irving associate professor of neurology and director of the program in neuroinfectious diseases at Columbia University Medical Center-New York Presbyterian Hospital.
Enhanced Diagnostic Capabilities
Delve Detect (search) uses metagenomic sequencing to identify viruses, bacteria, fungi, and parasites with a single test from a single sample, delivering 22% greater diagnostic yield compared to traditional methods. The technology provides comprehensive pathogen detection in an unbiased manner, enabling clinicians to identify the cause of central nervous system infections more quickly and completely.
The diagnostic advantages extend beyond speed to include detection of culture-negative infections and co-infections, which can be particularly challenging to diagnose using conventional methods. Real-world experience has demonstrated the test's ability to provide next-day results while covering bacterial, viral, fungal, and parasitic pathogens simultaneously.
Clinical and Economic Implications
The study's findings suggest significant benefits at both patient and institutional levels. Earlier diagnosis could reduce the burden of protracted clinical workups and hospital stays, while also alleviating disease burden for patients and clinicians.
"Getting an accurate diagnosis as soon as possible is critical for every patient, whether facing CNS infection (search) or autoimmune disease," said Brad Murray, chief executive officer of Delve Bio (search). "Earlier diagnoses are also important at the institutional level, reducing the burden of protracted clinical workups and hospital stays."
The research indicates that using comprehensive mNGS testing earlier in the diagnostic process could not only reduce costs but also enable faster initiation of targeted treatment. This is particularly relevant given that traditional testing often requires clinicians to run multiple tests over days and weeks while patients continue to progress.
Future Implementation Considerations
While the results are promising, researchers acknowledge that additional studies are needed to further quantify the real-world impact of mNGS testing and develop implementation strategies for healthcare institutions. The technology represents an important advancement in managing complex central nervous system infections, offering clinicians a powerful tool for rapid, comprehensive pathogen detection.
The study's modeling approach provides valuable insights into the potential benefits of earlier mNGS implementation, particularly for challenging cases where conventional diagnostic methods may fall short. As healthcare institutions consider adopting this technology, the data suggests substantial improvements in diagnostic efficiency and patient outcomes may be achievable.